SecBot SecBot
SECBOTREPLAY Home › Report › ARTV

ARTV · Artiva Biotherapeutics held its 2026 Annual Meeting on September 8,…

Artiva Biotherapeutics, Inc. · 8-K filed Sep 11, 2026 at 16:21 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Sep 11, 2026 at 16:21 ET

Artiva Biotherapeutics held its 2026 Annual Meeting on September 8, 2026, where stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the share reserve by 5,097,095 shares and modifying the annual automatic increase calculation to include pre-funded warrant shares. The meeting also saw the re-election of Class II directors Brian Daniels and Laura Stoppel, and the ratification of KPMG as auditor. This is a routine governance filing with no material financial impact.

  • Stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing authorized shares by 5,097,095 shares.
  • The amendment also modifies the annual automatic share reserve increase calculation to include shares issuable upon exercise of pre-funded warrants.
  • Class II directors Brian Daniels, M.D. and Laura Stoppel, Ph.D. were re-elected to three-year terms.
  • KPMG LLP was ratified as the independent registered public accounting firm for fiscal year 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access